Frequency, Risk Factors, and Outcomes of Central Nervous System Relapse in Lymphoma Patients Treated With Dose-Adjusted EPOCH Plus Rituximab

American Journal of Hematology - United States
doi 10.1002/ajh.24864
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Correction To: White Matter Changes in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate With or Without Rituximab

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2019English

Treatment of Central Nervous System Lymphoma in Rats With Intraventricular Rituximab and Serum

International Journal of Hematology
Hematology
2010English

Factors Associated With Risk of Central Nervous System Relapse in Patients With Non-Core Binding Factor Acute Myeloid Leukemia

American Journal of Hematology
Hematology
2017English

Effect of Intravitreous Rituximab Injections in Patients With Recurrent Ocular Lesions Associated With Central Nervous System Lymphoma

Archives of Ophthalmology
2008English

Advances in Risk Assessment and Prophylaxis for Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma

Haematologica
Hematology
2018English

A Case of Primary Cardiac Lymphoma Showing Isolated Central Nervous System Relapse

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2014English

Central Nervous System Relapse in Adolescents and Young Adults With Acute Lymphoblastic Lymphoma Treated With Total Body Irradiation and Hematopoietic Stem Cell Transplantation

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2019English

The Prognostic Role of Circulating Epstein-Barr Virus DNA Copy Number in Angioimmunoblastic T-Cell Lymphoma Treated With Dose-Adjusted EPOCH

Cancer Research and Treatment
Cancer ResearchOncology
2019English

Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated With Rituximab Plus Infusional EPOCH (AMC-034 Trial)

Clinical Cancer Research
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy